Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7381427 | ACLARIS | Seborrheic keratosis treatment |
Jun, 2022
(7 months ago) | |
US10098910 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
US9980983 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
US10493103 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
US10729720 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(12 years from now) | |
US9675639 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Jul, 2035
(12 years from now) |
Market Authorisation Date: 14 December, 2017
Treatment: Treatment of seborrheic keratoses that are raised
Dosage: SOLUTION;TOPICAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic